RxDoctor Payments Data

Andrew McAfee, MD

Family Medicine · Granger, INNPI 1558395079

Payments from drug & device makers

$13,949in general payments, 2019–2025

Across 929 payments — averaging $15.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Pfizer$851
  • Lilly USA, LLC$736
  • Merck$728
  • plus $7K from 50 others

What the payments were for

  • Food & beverage$13,87499%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,949 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$107,344
Medicare patients
308
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$85,613
FarxigaDapagliflozin Propanediol63$68,205
OzempicSemaglutide49$67,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$63,091
EliquisApixaban44$48,821
Tresiba Flextouch U-200Insulin Degludec13$41,214
Synjardy XrEmpagliflozin/Metformin Hcl34$38,819
JanuviaSitagliptin Phosphate37$35,531
Janumet XrSitagliptin Phos/Metformin Hcl32$28,288
XareltoRivaroxaban17$23,972
TrulicityDulaglutide13$23,695
MounjaroTirzepatide20$19,882
LinzessLinaclotide21$15,540
Tresiba Flextouch U-100Insulin Degludec22$10,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$8,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr$721$127,288143 claims
AstraZenecaFarxiga, Symbicort$1,367$74,52477 claims
GSKTrelegy Ellipta, Breo Ellipta$572$71,29087 claims
Novo NordiskOzempic$1,645$67,43749 claims
MerckJanuvia, Janumet Xr$728$63,82069 claims
PfizerEliquis, Premarin$851$52,27860 claims
Lilly USA, LLCTrulicity, Mounjaro$736$43,57833 claims
Johnson & JohnsonXarelto$429$23,97217 claims
AbbVieLinzess, Synthroid$1,850$18,94563 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Granger

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →